Online citations, reference lists, and bibliographies.

Effect Of Fruquintinib Vs Placebo On Overall Survival In Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial

Jin Li, Shukui Qin, Rui-Hua Xu, Lin Shen, Jianming Xu, Yuxian Bai, Lei Yang, Yanhong Deng, Zhen-dong Chen, Haijun Zhong, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianfeng Zhou, Nong Xu, Tianshu Liu, Dong Ma, Changping Wu, Ying Cheng, Donghui Chen, Wei Li, Sanyuan Sun, Zhuang Yu, Peiguo Cao, Haihui Chen, Ji-lei Wang, Shubin Wang, Hongbing Wang, Songhua Fan, Ye Hua, Weiguo Su
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Importance Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. Objective To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with metastatic CRC. Design, Setting, and Participants FRESCO (Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients) was a randomized, double-blind, placebo-controlled, multicenter (28 hospitals in China), phase 3 clinical trial. From December 2014 to May 2016, screening took place among 519 patients aged 18 to 75 years who had metastatic CRC that progressed after at least 2 lines of chemotherapy but had not received VEGFR inhibitor therapy; 416 met the eligibility criteria and were stratified by prior anti-VEGF therapy and K-ras status. The final date of follow-up was January 17, 2017. Interventions Patients were randomized in a 2:1 ratio to receive either fruquintinib, 5 mg (n = 278) or placebo (n = 138) orally, once daily for 21 days, followed by 7 days off in 28-day cycles, until disease progression, intolerable toxicity, or study withdrawal. Main Outcomes and Measures The primary end point was overall survival. Key secondary efficacy endpoints were progression-free survival (time from randomization to disease progression or death), objective response rate (confirmed complete or partial response), and disease control rate (complete or partial response, or stable disease recorded ≥8 weeks postrandomization). Duration of response was also assessed. Safety outcomes included treatment-emergent adverse events. Results Of the 416 randomized patients (mean age, 54.6 years; 161 [38.7%] women), 404 (97.1%) completed the trial. Median overall survival was significantly prolonged with fruquintinib compared with placebo (9.3 months [95% CI, 8.2-10.5] vs 6.6 months [95% CI, 5.9-8.1]); hazard ratio (HR) for death, 0.65 (95% CI, 0.51-0.83; P < .001). Median progression-free survival was also significantly increased with fruquintinib (3.7 months [95% CI, 3.7-4.6] vs 1.8 months [95% CI, 1.8-1.8] months); HR for progression or death, 0.26 (95% CI, 0.21 to 0.34; P < .001). Grades 3 and 4 treatment-emergent adverse events occurred in 61.2% (170) of patients who received fruquintinib and 19.7% (27) who received placebo. Serious adverse events were reported by 15.5% (43) of patients in the fruquintinib group and 5.8% (8) in the placebo group, with 14.4% (40) of fruquintinib-treated and 5.1% (7) of placebo-treated patients requiring hospitalization. Conclusions and Relevance Among Chinese patients with metastatic CRC who had tumor progression following at least 2 prior chemotherapy regimens, oral fruquintinib compared with placebo resulted in a statistically significant increase in overall survival. Further research is needed to assess efficacy outside of China. Trial Registration ClinicalTrials.gov Identifier: NCT02314819
This paper references
10.1007/s00280-016-3069-8
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors
Junning Cao (2016)
Survival Analysis Using SAS: A Practical Guide
Paul D. Allison (1995)
10.3322/caac.21338
Cancer statistics in China, 2015.
Wanqing Chen (2016)
10.1200/JCO.2012.42.8201
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Eric Van Cutsem (2012)
10.1200/JCO.2004.11.037
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Axel M Grothey (2004)
10.1016/S0140-6736(00)02034-1
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
J-Y. Douillard (2000)
10.1016/S1470-2045(15)70156-7
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jin Li (2015)
10.1001/jamaoncol.2016.5688
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice (2017)
10.1016/S1470-2045(14)70330-4
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Volker Heinemann (2014)
10.4161/15384047.2014.964087
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
Qiaoling Sun (2014)
Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer
Ma Dong (2006)
10.1016/S0140-6736(12)61900-X
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel M Grothey (2013)
10.1200/JCO.2007.14.9930
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Leonard B Saltz (2008)
10.15611/ekt.2014.3.07
Extensions of Cox Model for Non-Proportional Hazards Purpose
Jadwiga Borucka (2014)
10.1200/JCO.2009.27.4860
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Jean-yves Douillard (2010)
10.1517/13543784.2016.1161754
Novel anti-angiogenic therapeutic strategies in colorectal cancer
Marco Tampellini (2016)
10.1186/s13045-016-0384-9
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
Rui-Hua Xu (2017)
10.1200/JCO.2005.06.081
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Daniel J. Hicklin (2005)
10.1200/JCO.2000.18.16.2938
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Aimery de Gramont (2000)
10.1056/NEJMoa1414325
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Robert J. Mayer (2015)
10.1200/jco.2004.22.90140.3001
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).
George D. Demetri (2004)
10.1111/j.1447-0756.2001.tb01222.x
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.
Christiane (2002)
10.1093/annonc/mdw101
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Hui Yan Luo (2016)
Global Burden of Disease Cancer
C Fitzmaurice (2016)
10.1200/jco.2012.30.4_suppl.lba385
Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
Axel M Grothey (2012)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Marie-Paule Sablin (2010)



This paper is referenced by
10.1186/s13045-019-0718-5
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Shuang Qin (2019)
10.1080/13696998.2020.1717500
Treatment patterns and direct medical costs of metastatic colorectal cancer patients: A retrospective study of electronic medical records from urban China.
Lin Shen (2020)
10.21037/23644
Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?
Caterina Mecca (2019)
10.1097/MD.0000000000013635
Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
Xiaoli Liao (2018)
10.1177/0300891620916789
Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer.
Pengfei Zhang (2020)
10.1016/J.CLCC.2018.11.002
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
Tanios S. Bekaii-Saab (2019)
10.1016/j.critrevonc.2020.102877
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018.
Pasquale Lombardi (2020)
10.21147/j.issn.1000-9604.2019.03.03
Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018
Ying Yuan (2019)
10.1007/s00384-020-03571-5
A systematic review of salvage therapies in refractory metastatic colorectal cancer
Fausto Petrelli (2020)
10.2217/fon-2018-0454
Fruquintinib and its use in the treatment of metastatic colorectal cancer.
Yanhong Deng (2019)
10.1007/s40265-018-0998-z
Fruquintinib: First Global Approval
Matt Shirley (2018)
10.3390/cancers12051214
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Eleonora Lai (2020)
10.1016/j.clcc.2020.04.003
Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion.
Ana Fernández-Montes (2020)
10.1158/1078-0432.CCR-18-3001
The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy
Jin Cheng (2019)
10.2147/CMAR.S215533
Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer
Ying Zhang (2019)
10.3389/fgene.2020.00096
Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases
Yaolin Song (2020)
10.2147/CMAR.S244486
Functions and Clinical Significance of UPF3a Expression in Human Colorectal Cancer
Xinmin Bao (2020)
10.1007/s00432-019-02964-6
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
Zhu Jing (2019)
10.1080/1120009X.2019.1692282
Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis
Xiao-Jun Liang (2019)
10.1007/s00432-018-2795-1
Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018)
Jianmin Xu (2018)
10.3329/bjp.v14i1.38807
Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
Kun Dong (2019)
10.1080/17512433.2019.1630272
The clinical application of fruquintinib on colorectal cancer
Zhongguang Chen (2019)
DDDT_A_199362 2865..2871
Yibin Mei (2019)
10.1186/s12885-020-6557-5
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China
Rui-Hua Xu (2020)
10.1038/s41392-020-0116-z
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie (2020)
10.1007/s00384-019-03477-x
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Qi Zhang (2019)
10.1080/1120009X.2020.1728860
Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
Meihui Cao (2020)
10.1016/j.clinthera.2019.05.014
Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects.
Hongjie Qian (2019)
10.12659/MSM.918411
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials
Jianxin Chen (2019)
10.1038/s41598-020-62961-5
Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
Fen Wang (2020)
10.2147/CMAR.S196170
Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
Datian Chen (2019)
10.1634/theoncologist.2019-0164
A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
Xiaofeng Chen (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar